Catalyst Event
Eli Lilly and Co (LLY) · Other
From Akros SCHK HK-U.S. Biotech Index (ASHUBIO)
5/12/2026, 12:00:00 AM
Eli Lilly announced positive late-stage trial results showing patients maintained long-term weight loss by switching from high-dose injectable GLP-1s to lower-dose Zepbound or the oral pill Foundayo (orforglipron).
Korean Translation
일라이 릴리, 고용량 주사형 GLP-1에서 저용량 제프바운드 또는 경구용 알약 파운다요(오르포글리프론)로 전환한 환자들이 장기적으로 체중 감소를 유지했다는 긍정적인 후기 임상시험 결과를 발표함.
Related Recent Events
3SBio Inc (1530) · Earnings Release
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
8/26/2026, 12:00:00 AM
3SBio Inc (1530) · Other
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
7/21/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
Giant Biogene Holding Co Ltd (2367) · Other
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
6/1/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
5/27/2026, 12:00:00 AM